liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab
Orebro University Hospital.
Sahlgrens University Hospital.
Sahlgrens University Hospital.
Norrlands University Hospital.
Show others and affiliations
2011 (English)In: ANNALS OF NEUROLOGY, ISSN 0364-5134, Vol. 69, no 1, 83-89 p.Article in journal (Refereed) Published
Abstract [en]

Objective: The impact of present disease-modifying treatments (DMTs) in multiple sclerosis (MS) on nerve injury and reactive astrogliosis is still unclear. Therefore, we studied the effect of natalizumab treatment on the release of 2 brain-specific tissue damage markers into cerebrospinal fluid (CSF) in MS patients. Methods: CSF samples from 92 patients with relapsing forms of MS were collected in a prospective manner prior to natalizumab treatment and after 6 or 12 months. In 86 cases, natalizumab was used as second-line DMT due to breakthrough of disease activity. The levels of neurofilament light (NFL) and glial fibrillary acidic protein (GFAP) were determined using highly sensitive in-house developed enzyme-linked immunosorbent assays. Results: Natalizumab treatment led to a 3-fold reduction of NFL levels, from a mean value of 1,300 (standard deviation [SD], 2,200) to 400 (SD, 270) ng/l (p andlt; 0.001). The later value was not significantly different from that found in healthy control subjects (350ng/l; SD, 170; n = 28). Subgroup analysis revealed a consistent effect on NFL release, regardless of previous DMT or whether patients had relapses or were in remission within 3 months prior to natalizumab treatment. No differences between pre- and post-treatment levels of GFAP were detected. Interpretation: Our data demonstrate that natalizumab treatment reduces the accumulation of nerve injury in relapsing forms of MS. It is anticipated that highly effective anti-inflammatory treatment can reduce axonal loss, thereby preventing development of permanent neurological disability.

Place, publisher, year, edition, pages
John Wiley and Sons, Ltd , 2011. Vol. 69, no 1, 83-89 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-65960DOI: 10.1002/ana.22247ISI: 000286850800014OAI: diva2:400659
Available from: 2011-02-28 Created: 2011-02-28 Last updated: 2012-03-23

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Dahle, CharlotteVrethem, Magnus
By organisation
Clinical ImmunologyFaculty of Health SciencesDepartment of Clinical Immunology and Transfusion MedicineNeurologyDepartment of Neurology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 27 hits
ReferencesLink to record
Permanent link

Direct link